828 related articles for article (PubMed ID: 8230644)
1. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced torsade de pointes.
Raehl CL; Patel AK; LeRoy M
Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
4. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
[TBL] [Abstract][Full Text] [Related]
5. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
6. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
[TBL] [Abstract][Full Text] [Related]
7. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
Tran HT; Chow MS; Kluger J
Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
9. Experimental models of torsades de pointes.
Weissenburger J; Davy JM; Chézalviel F
Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
[TBL] [Abstract][Full Text] [Related]
10. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic drugs and torsade de pointes.
Lazzara R
Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
Cubeddu LX
Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
[TBL] [Abstract][Full Text] [Related]
13. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
Hohnloser SH; Klingenheben T; Singh BN
Ann Intern Med; 1994 Oct; 121(7):529-35. PubMed ID: 8067651
[TBL] [Abstract][Full Text] [Related]
14. Torsades de pointes, a common arrhythmia, induced by medication.
Ko PT; Gulamhusein S; Kostuk WJ; Klein GJ
Can Med Assoc J; 1982 Sep; 127(5):368-72. PubMed ID: 7104914
[TBL] [Abstract][Full Text] [Related]
15. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
[TBL] [Abstract][Full Text] [Related]
16. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
18. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Wolbrette DL
Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
[TBL] [Abstract][Full Text] [Related]
19. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Singh BN; Kehoe R; Woosley RL; Scheinman M; Quart B
Am Heart J; 1995 Jan; 129(1):87-97. PubMed ID: 7817931
[TBL] [Abstract][Full Text] [Related]
20. [Sotalol and torsades de pointes ventricular tachycardia].
Petersen HH; Sandøe E
Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
